Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applications Accelerates expansion into new modality markets with a unique, scalable ...

Repligen Corporation RGEN reported fourth-quarter 2025 adjusted earnings per share of 49 cents, which came ahead of the Zacks Consensus Estimate and the year-ago adjusted earnings of 44 cents per ...

A month has gone by since the last earnings report for Repligen (RGEN). Shares have lost about 11.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Repligen (RGEN – Research Report) on July 30 and set a price target of $200.00. Puneet Souda has given his Buy rating due to a ...

Repligen’s second quarter results were met with a significant positive response from the market, reflecting robust top-line performance and strong operational execution. Management attributed the ...

Repligen Earnings: Double-Digit Revenue Growth and Margin Improvement To Continue in 2026 Repligen reported year-on-year revenue growth of 14% for the quarter and 16% for the year. Full-year adjusted ...

Accelerates expansion into new modality markets with a unique, scalable purification solution Strongly synergistic with AVIPure ® affinity ligands and OPUS ® pre-packed chromatography columns WALTHAM, ...